February #32 : Green Means Go

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

Marked Man

Warts and All

Cracker Jack

Names Will Never Hurt You?

War on the Warts

Rub a Drug Flub

Déjà Vu

Green Means Go

The Cutting Edge

Sealed w/KS

Shalala Infections

An Ad Is an Ad Is an Ad

ADAP Tapped

Trojan Wars

Girls on Trial

The Pill Drill

Say What

Tapped for Greatness

My Brother

Honey, Mud, Maggots, and Other Medical Marvels

Carmine’s Story

There Is Hope: Learning to Live With HIV

Crocodile Tears

The Kinsey Sicks

Gridlock’d

CATIE

Cocktails: The Morning After

Patrolling the Borders

AIDSpeak

Instruments of Infection

Hiccup Blues

A New Kind of Waisting

.38 Caliber

The Labors for Your Fruits

Barbed Comments

Party Planner

Hollywood Golightly

At the End of My Hope

Criminal Body

I Got All My Sistahs With Me

Primo Chemo

S.O.S.

Mailbox

POZ Stars

OBITS



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

February 1998

Green Means Go

The NIH throws a party?--uh, study

San Francisco researchers stoked up the victory pipe as the feds gave a green light to medical marijuana studies. “We’ve been trying to do a study for four years,” said Dr. Donald Abrams of the University of California, San Francisco, who spearheaded the effort. A million-dollar grant from the National Institutes of Health (NIH) ended a protracted struggle for the researcher, who is finally able to study pot’s interaction with protease to determine whether toking renders the anti-HIV drugs dangerous or ineffective. “Our concern would be that Marinol or marijuana smoke would have an adverse affect on Crixivan [indinavir],” Abrams said, adding that pot is metabolized by the same liver enzymes that process protease inhibitors.

The two-year study will compare PWAs on Crixivan (the most commonly prescribed anti-protease) who ingest Marinol (a pill containing THC, the active ingredient in pot) and those who smoke marijuana (provided by the National Institute on Drug Abuse) with a control group taking only placebo. Researchers will look at the drug’s impact on viral loads, hormones and the immune system, as well as appetite and weight gain.

The 63 PWAs lighting up research reefers and popping pot pills are enrolled for 21-days at the San Francisco General Hospital. If dooby use is determined to be innocuous, a follow-up study will be initiated. The results are expected to play a key role in the debate over the medical use of marijuana for PWAs. One major pro-pot advocate is certain of the outcome. “I know this experiment will work because I know marijuana gives you the munchies,” said the Cannabis Cultivator Club’s Dennis Peron.


Search: NIH, marijuana




[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dambitious
    Gone
    New York


    RyGuy00
    New York
    New York


    usuallyhappy
    Palm Springs
    California


    josebos
    Boston strong
    Massachusetts
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.